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Background: Glycoprotein IIB/IIIA inhibitors are occasionally utilized during carotid artery
stenting (CAS) in the presence or absence of a visualized intra-operative thrombus.
Objective: We assess the hemorrhagic and clinical outcomes associated with the use of
eptifibatide during CAS.
Methods:A retrospective analysis of prospectively collected data on patients with the diag-
nosis of carotid artery stenosis underwent CAS in a single center. We identified those who
received intravenous eptifibatide intra-operatively and compared to the rest of the cohort.
Hemorrhagic outcomes included intracerebral hemorrhage (ICH) or groin hematoma that
occurred during the hospital stay.
Results: In this analysis, 81 patients had CAS during a 3-year span; 16 of those had
received 15 mg of intravenous eptifibatide intra-operatively. The mean age of the treated
and untreated patients was similar (65.6±13.4 versus 65.4±10.2; P =0.13). One patient
(1.2%) in this series had ICH in the perioperative period that occurred in the non-eptifibatide
group. Five patients (6.2%) in this series had groin hematoma; only one in the non-
eptifibatide group required surgical repair. No mortality was reported and clinical outcomes
including discharge modified Rankin scale, NIH stroke scale, as well as discharge destina-
tion were similar in both groups. A stratified analysis among those who underwent an
urgent CAS showed no significant differences in the risks of hemorrhages or any clinical
outcome (P >0.05).
Conclusion: The use of eptifibatide during CAS is safe. The risk of any hemorrhagic com-
plication is rare in this series; however, a prospective study to validate this observation will
be helpful.
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INTRODUCTION
In-stent thrombosis is a potential problem associated with carotid
artery stenting (CAS); a process attributed to intimal injury during
percutaneous arterial interventions resulting in platelet activation
and thrombus formation (Gawaz et al., 1996). Some of these
processes occur intra-operatively and can be visualized angio-
graphically. Glycoprotein (GP) IIb/IIIa antagonists are a group
of drugs that are employed during percutaneous interventional
procedures; they work by binding to the GP IIb/IIIa receptors
with subsequent inhibition of platelet aggregation and throm-
bus formation. The GP IIb/IIIa inhibitors may be helpful agents
in decreasing the rate of periprocedural ischemic events asso-
ciated with CAS (Kapadia et al., 2001; Chaturvedi and Yadav,
2006). Eptifibatide is a cyclic peptide derivative that reversibly
binds GP IIb/IIIa (Braunwald, 2011). Unlike other agents, intra-
venous eptifibatide infusion produces high levels of unbound
drug. However, its short plasma half-life of approximately 2.5 h
allows for rapid clearance and hence, the reversal of platelet
inhibition when administration is discontinued. Platelet aggrega-
tion has been shown to return to normal in approximately 2–4 h,
with the bleeding time normalizing within 1 h (Schror and Weber,
2003).
Because of the transient platelet inhibition, few reports sug-
gested an increased rate of intracerebral hemorrhage (ICH)
associated with the use of GP IIb/IIIa antagonists (Chaturvedi
and Yadav, 2006). In this series, we assess the incidence of hemor-
rhagic complications associated with the use of eptifibatide during
CAS. In addition, we assess functional outcome, mortality rate, and
length of hospital stay.
MATERIALS AND METHODS
Approval from the Institutional Review Board was given for our
prospective database and an exempt was given to this study. We
reviewed all CAS procedures in our database between July 1,
2009 and June 30, 2011; and a cohort of consecutive patients
who underwent CAS was selected for analysis. Procedure records
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were examined including the physician’s procedure report, nurs-
ing notes, hospital progress notes, and discharge summaries.
We excluded patients if carotid revascularization was emergently
needed due to ischemic symptoms occurring within 8 h from
onset including those who underwent mechanical thrombec-
tomy. Patients were grouped according to the need for intra-
operative administration of intravenous eptifibatide. This need
was determined by the primary operator whether for thera-
peutic or preventative purposes. In addition to patient demo-
graphics and vascular risk factors, we collected information on
the symptomatic status, preoperative modified Rankin Score
(mRS), preoperative NIH stroke Scale (NIHSS), severity of the
carotid stenosis, and whether patients were pre-treated with
clopidogrel.
INSTITUTION PROTOCOL FOR CAS
Any patient undergoing CAS must meet the center for Medicare
and Medicaid services eligibility criteria for high risk sympto-
matic carotid disease or have high-grade asymptomatic stenosis
in the setting of high-risk clinical features (Krajcer, 2005). Two
groups of patients were included in this analysis; first, those who
were electively admitted but had a qualifying event of stroke or
TIA in the prior 3 months, or high risk severe asymptomatic
stenosis. The second group included patients admitted for a diag-
nosis of TIAs or mild stroke and urgent CAS was needed due to
fluctuating neurological symptoms or recurrent TIAs (but after
8 h from symptoms onset). Patients with a large core infarction
(more than 20% of the territory supplied by the middle cere-
bral artery) based on brain MRI and computerized tomography
scans are excluded from immediate CAS, i.e., revascularization
during the first 4 weeks from the onset of the ischemic strokes. The
severity of the stenosis based on carotid angiography was mea-
sured using the North American Symptomatic Endarterectomy
Trial criteria methodology (North American Symptomatic Carotid
Endarterectomy Trial Collaborators, 1991). In the pre-operative
period, patients received dual antiplatelet therapy with Aspirin
(325 mg daily) and clopidogrel (75 mg daily) for at least 3 days.
If the patient had not been on clopidogrel for at least 3 days, a
300 mg bolus was administered at least 6 h prior to performing the
CAS. CAS procedures were performed in a bi-plane angiography
suite under conscious sedation; with vascular access through the
femoral artery. Once the femoral sheath was in place, all patients
received a bolus of intravenous heparin to achieve activated clot-
ting time of 250–350 s (Saw et al., 2006). Distal embolic protection
device was utilized in all cases; this was followed by a mono-rail
stent assisted balloon angioplasty, and stent deployment. If angio-
graphic platelet aggregation or thrombus formation is visualized,
a bolus of 15 mg of eptifibatide is administered intravenously.
Occasionally, eptifibatide was used preventatively if clopidogrel
was not given pre-operatively. No patients were placed on con-
tinuous intravenous eptifibatide drips. At the conclusion of the
CAS procedure, a vascular closure device, or manual compres-
sion of the femoral artery was used based on operator preference,
the presence of vascular disease in the femoral angiography, or
a puncture site at the femoral bifurcation. All patients after CAS
were admitted to the neurointensive care unit for close hemo-
dynamic and neurological monitoring and management. Critical
care management may last for 24–48 h or longer if symptomatic
management of the blood pressure is needed or clinical event had
occurred.
STATISTICAL ANALYSIS AND OUTCOMES
Chi-square and Fisher’s exact tests were used to compare cate-
gorical proportions; and t -test and Wilcoxon rank sum test were
used to compare the mean and median of continuous variables.
The primary outcome was ICH that was identified during the
hospital stay or after patients were discharged from the hospi-
tal. ICH was identified by conventional or DYNA computerized
tomography scans, and confirmed by MRI when appropriate. All
groin hematomas were reported including the clinically signifi-
cant hematoma (hematoma that needed a surgical repair or blood
transfusion). In addition, we identified functional outcomes based
on the discharge mRS as well as the NIHSS. Lastly, we assessed the
length of stay, discharge locations, and hospital mortality rates. A
stratified analysis was performed for those who were hospitalized
for acute stroke or TIA and in whom CAS was performed during
the same hospital stay.
RESULTS
From the initial sample of 87 patients, 6 were excluded because was
performed as part of an intervention for ongoing acute ischemic
stroke, including those who underwent mechanical thrombec-
tomy. Eighty one patients with the mean age of 65.5 were included
in this analysis; 16 were treated with eptifibatide during CAS. The
mean age of the treated and untreated population was similar
(65.6± 13.4 versus 65.4± 10.2; P = 0.13). Males were predomi-
nant in both groups (75 versus 64.1%; P = 0.4). Eight patients
(9.8%) were asymptomatic with the remainder of the sample hav-
ing had TIA, stroke, or amaurosis fugax, 22.2, 62.9, and 3.7%,
respectively. The proportion of symptomatic patients did not dif-
fer in each group (Table 1). Fourteen of 16 (87.5%) patients in
the eptifibatide group and 42/65 (64.6%) in the non-eptifibatide
group had acute stroke or TIA upon presentation and underwent
CAS during the same hospital stay (P = 0.07). Vascular risk fac-
tors of diabetes, hypertension, coronary, and peripheral arterial
disease, hyperlipidemia, history of TIA or stroke, and smoking
were similar in both groups (P > 0.05). Similarly, the mean mRS
(1.18± 1.10 versus 0.84± 0.91) upon initial hospitalization as well
as the stroke severity (NIHSS: 1.75± 2.26 versus 2.06± 2.70) were
similar in both groups (P > 0.05).
In this cohort, one patient in the non-eptifibatide group (1.2%)
had ICH following CAS that was attributed to reperfusion syn-
drome (Wu et al., 2012). Five patients developed groin hematomas
in this cohort, only one was deemed as clinically significant
occurred in the non-eptifibatide group and required vascular
repair. Among the eptifibatide group, one patient (6.2%) had a
groin hematoma that did not require blood transfusion or sur-
gical intervention. Functional status measured by discharge mRS
was similar in both groups (0.54± 0.74 versus after 0.88± 0.98).
The length of hospital stay was similar in both groups (P = 0.44).
In this cohort, no mortality was reported and 56 of 81 patients
(69.1%) discharged to home; and 25 (30.8%) patients discharged
to rehabilitation centers. Angiographically, this cohort demon-
strated severe carotid disease with the mean stenosis rate of 84.1%;
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which was similar in both groups (Table 1). Postoperatively,
the stenosis rate was 13.7%; which again was similar in both
groups (Table 2). All patients were pre-treated with aspirin before
Table 1 | Cohort demographics.
CAS+
eptifibatide
N =16
CAS−
eptifibatide
N =65
P value
Age (mean±SD) 65.6±13.4 65.4±10.2 0.13
GENDER n (%)
Female 4 (25.0) 23 (35.9) 0.40
Male 12 (75.0) 41 (64.1)
SYMPTOMATIC STATUS n (%)
Asymptomatic 2 (13.3) 6 (9.23) 0.47
TIA 3 (20.0) 15 (23.1)
Stroke 10 (66.7) 41 (63.1)
Amourosis Fugax 0 3 (4.6)
TIA or stroke upon initial
presentation* n (%)
14 (87.5) 42 (64.6) 0.07
VASCULAR RISK FACTORS n (%)
Diabetes 5 (31.2) 22 (33.8) 0.84
Hypertension 14 (87.5) 58 (89.2) 0.84
Coronary artery disease 10 (62.5) 27 (41.5) 0.13
Hyperlipidemia 11 (68.7) 45 (69.2) 0.97
Smoking 6 (37.5) 19 (29.2) 0.52
Peripheral artery disease 1 (14.3) 8 (27.6) 0.46
TIA or stroke 8 (53.3) 32 (50.8) 0.85
PRE-STENT (MEAN±SD)
mRS 1.18±1.10 0.84±0.90 0.26
NIHSS 1.75±2.26 2.06±2.70 0.86
Stenosis severity rate 82.62±25.6 84.9±14.8 0.72
Pre-stent clopidogrel n (%) 14 (87.5) 58 (89.2) 0.84
*This group had acute neurological changes of either TIA or small stroke and
carotid artery stenting (CAS) performed during the same hospital stay.
CAS; 72 patients (88.9%) were given clopidogrel prior to the
procedure. When the sample was stratified by those who under-
went urgent CAS during the same hospital stay, similar results
were found (Table 2). No ICH or mortality was reported but four
groin hematomas (one in the eptifibatide treated and four in the
non-eptifibatide groups).
DISCUSSION
Intimal injury during CAS may lead to collagen exposure with sub-
sequent activation of procoagulant factors with the end result of
a platelet-rich thrombus formation. In some instances, thrombus
formation may cause occlusion of a cerebral blood vessel with
subsequent ischemic stroke. Interventionalists utilize GP IIb/IIIa
inhibition during CAS either therapeutically to treat acute in-stent
thrombosis or preventatively to reduce the risk of periprocedural
thrombus formation. Few reports suggested that the use of GP
IIb/IIIa inhibitors alone or in combination with intra-arterial
thrombolysis may lead to successful revascularization of an acutely
thrombosed stent during CAS (Tong et al., 2000; Steiner-Boker
et al., 2004). In a retrospective review of 254 CAS procedures,
Green et al. identified two patients with witnessed thromboem-
bolic events occurred intra-operatively. In both patients, the
thrombotic events occurred during the initial passage of the filter
wire through the proximal lesion. Nevertheless, both patients were
successfully treated with intra-arterial urokinase and intravenous
GP IIb/IIIa inhibitor (abciximab; Green et al., 2005). Adjunctive
use of GP IIb/IIIa inhibitors during interventional procedures has
been shown to decrease the risk of periprocedural ischemic events
(Qureshi et al., 2004; Dumont et al., 2012). Most of these data
were abstracted from the cardiology literature, which has shown
that the adjunctive use of GP IIb/IIIa inhibitors in the setting
of percutaneous coronary intervention significantly reduces the
rates of 30-day mortality and myocardial Infarction, as well as
reduces the need for repeat revascularization procedures (Labi-
naz et al., 2007; Winchester et al., 2011). These beneficial effects
were achieved at an increased risk of thrombocytopenia and minor
bleeding.
Table 2 | Outcomes associated with carotid artery stenting (CAS) in association with the use of eptifibatide among all patients, and a subgroup
of patients with acute stroke or transient ischemic attacks followed by urgent CAS.
All patients with CAS Patients with urgent CAS
CAS+
eptifibatide
N =16
CAS−
eptifibatide
N =65
P value CAS+
eptifibatide
N =14
CAS−
eptifibatide
N =43
P value
Intracerebral hemorrhage n (%) 0 1 (1.5) 0.61 0 0 –
Any groin hematoma n (%)* 1 (6.2) 4 (6.1) 0.98 1 (7.1) 3 (7.1) 0.99
Post-stent stenosis rate (mean±SD) 7.66±9.42 14.0±18.8 0.34 8.21±9.52 14.5±20.3 0.51
Discharge mRS (mean±SD) 0.54±0.74 0.88±0.98 0.21 0.61±0.76 1.07±1.27 0.18
Discharge NIHSS (mean±SD) 1.20±1.65 1.83±2.79 0.51 1.38±1.70 2.46±3.25 0.37
Length of stay – days (mean±SD) 3.66±3.1 4.7±4.9 0.66 4.1±3.1 6.27±5.54 0.20
DISCHARGE LOCATION n (%)
Home 11 (64.7) 45 (69.2) 0.54 8 (61.5) 25 (60.9) 0.97
Rehabilitation center 5 (31.2) 20 (31.2) 5 (38.5) 16 (39.1)
*Any groin hematoma refers to all hematoma that are clinically and non-clinically significant.
www.frontiersin.org February 2013 | Volume 4 | Article 4 | 3
Allam et al. Epitifibatide in urgent carotid stenting
In our study, we found a low risk of ICH and groin hematoma
associated with the use of eptifibatide during CAS. The overall
rate of ICH in our cohort (1.2%) is compatible with previous
reports which ranged between 0.36 and 4.1% (Cheung et al., 2003;
Moulakakis et al., 2009). None of the 14 patients with acute stroke
and treated with eptifibatide during CAS had ICH. There has
been contradicting safety data regarding the use of GP IIb/IIIa
inhibitors during CAS (Qureshi et al., 2002; Chan et al., 2005;
Kramer et al., 2007; Zahn et al., 2007) however, most of these
studies were focused on abciximab during CAS. Kapadia et al.
evaluated 151 patients with CAS, 128 of those had been prophylac-
tically treated with abciximab while the rest of cohort was treated
with intravenous heparin. At 30-days, the thromboembolic rates
were significantly less in the abciximab group (1.6 versus 8%) with
one patient developed ICH in the abciximab group (Kapadia et al.,
2001). The authors suggested a relative safety of abciximab dur-
ing CAS. On the contrary, Wholey et al. shown higher rates of
thromboembolic events (6 versus 2.4%) as well as hemorrhages
in abciximab group compared to intravenous heparin. Two of
four neurologically related deaths in the abciximab group were
due to large ICH compared to no hemorrhages in the heparin
group (Wholey et al., 2003). These observations led the authors
to conclude relative risks associated with the use of GP IIb/IIIa
inhibitors during CAS. A recent change in focus to the use of epti-
fibatide during cardiac interventional procedures has been noted
by neurointerventionalists (Mahmoudi et al., 2011). Eptifibatide
has a shorter life span compared to abciximab and hence, may
have a better safety profile. The safety and efficacy of eptifibatide
was assessed in a small sample of CAS patients treated with high-
dose eptifibatide administered as intravenous bolus followed by
continuous infusion over 20–24 h post-operatively (Qureshi et al.,
2004; Dumont et al., 2012). Again the authors suggested epti-
fibatide was safe to use during CAS. Besides the absent risk of
ICH in our eptifibatide group, no mortality was reported despite
the fact that more than half of our patients had CAS performed
urgently.
This study is limited by the small sample of those who were
treated with eptifibatide during CAS, thus may have led to a selec-
tion bias. In addition, the use of eptifibatide in our series was not
uniform, i.e., eptifibatide was given for therapeutic and preventa-
tive purposes. Regardless, this study suggests the relative safety of
eptifibatide use during CAS when performed electively or urgently.
Risk-benefit assessment in large prospective studies or national
registry would be useful.
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